THE CARDIOVASCULAR EFFECTS OF BROMOCRIPTINE IN PARKINSONISM
- 1 August 1976
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 3 (4), 571-574
- https://doi.org/10.1111/j.1365-2125.1976.tb04877.x
Abstract
The cardiovascular effects of bromocriptine, a dopamine receptor agonist, were investigated in twenty-eight Parkinsonian patients. Bromocriptine caused a significant impairment of postural compensation with a fall in systolic pressure and an absence of the rise in diastolic pressure after standing for 1 min when patients taking active drug were compared to the same patients on placebo. The hypotensive effect persisted for at least 6 weeks of treatment. There was also a significant reduction in supine heart rate. One patient had marked falls in supine and erect blood pressure after a single oral dose of bromocriptine (2.5 mg) and a further patient developed paroxysmal atrial tachyarrhythmias. Both blood pressure and heart rate changes reversed spontaneously after stopping bromocriptine. It is proposed that dopaminergic mechanisms either in the central nervous system or the periphery contribute to cardiovascular regulation in man.Keywords
This publication has 15 references indexed in Scilit:
- IDIOPATHIC PARKINSONISM TREATED WITH BROMOCREPTINEThe Lancet, 1975
- DOPAMINE IS AN IMPORTANT NEUROTRANSMITTER IN THE AUTONOMIC NERVOUS SYSTEMThe Lancet, 1975
- Bromocriptine treatment of acromegaly.BMJ, 1975
- Bromocriptine in ParkinsonismBMJ, 1974
- Long-term Treatment of Galactorrhoea and Hypogonadism with BromocriptineBMJ, 1974
- ORTHOSTATIC HYPOTENSION IN PARKINSON'S DISEASEThe Lancet, 1972
- Assessment of Autonomic Function in Patients with a Parkinsonian SyndromeBMJ, 1971
- PREVENTION OR REVERSAL OF LEVODOPA-INDUCED CARDIAC ARRHYTHMIAS BY DECARBOXYLASE INHIBITORSThe Lancet, 1970
- Evidence for a centrally mediated hypotensive effect of L-dopa in the ratJournal of Pharmacy and Pharmacology, 1970
- Hypotension Caused by L-DopaBMJ, 1970